However, the latter study’s results warrant interpretation with caution, because they only refer to B-ALL cases, subtype prevalence is far beyond expected (no hyperdiploid cases, 21% with TCF3::PBX1, 14% with BCR::ABL1, and only 7% with ETV6::RUNX1), genotyping failed in 17–19% of cases, and there were significant differences between patients and controls as regards age, sex, and ancestry. This evidence concerns the gene BCR and acute lymphoblastic leukemia.